CompletedPHASE4NCT07336420

Treatment Patterns, Medication Usage, Effectiveness, and Safety Among US Veterans Using the Remote Electrical Neuromodulation (REN) Wearable Device for Migraine Treatment

Sponsor: Theranica

Trial Details

Condition	Migraine, Acute Treatment of Migraine
Intervention	Nerivio REN device
Phase	PHASE4
Status	Completed
Participants	466
Est. Completion	25 Jan 2026
Last Updated	3 Apr 2026

Primary Outcome

Rescue Medication Usage

Eligibility Criteria

Inclusion Criteria

Inclusion Criteria: * VA patients who were prescribed the Nerivio REN device * Performed at least 2 REN treatments with both baseline and 2-hours reports Exclusion Criteria: • None

Trial Sites

Countries

United States

View Registry Entry

Related Analysis

Phase IV Real-World Study Reveals Nerivio Electrical Neuromodulation Reduces Rescue Medication Use in US Veterans with Migraine

A Phase IV real-world study of 466 US veterans demonstrates that the Nerivio electrical neuromodulation device significantly reduces rescue medication usage for acute migraine treatment. This landmark study provides crucial evidence for non-pharmacological migraine management in veteran populations.

Read full article →

This content is for educational purposes for healthcare professionals only and does not constitute clinical advice. Clinical decisions should be based on individual patient assessment, current guidelines, and appropriate specialist consultation. Editorial Standards · Privacy Policy · Terms of Service